Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPositive Phase IIb Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Post-Herpetic Neuralgia
XenoPort, 09/18/09
GlaxoSmithKline and XenoPort, Inc. announced top–line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 for neuropathic pain associated with post–herpetic neuralgia in adults. In this study, subjects were randomized to receive placebo, 1200, 2400 or 3600 mg/day of GSK1838262 dosed twice a day.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Multiple Doses of Clarithromycin on the Pharmacokinetics of Laropiprant in Healthy Subjects
Cardiovascular Drug Reviews, 03/12/10
The Use and Limitations of Unfractionated Heparin
Critical Pathways in Cardiology, 03/11/10
Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study
BMC Pulmonary Medicine, 03/10/10
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
Cytokinetics, 03/12/10
Two Drugs Fail in Trials
PharmExec, 03/11/10
Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
AstraZeneca, 03/10/10
Article Search
Sponsor
Sponsor